|
|
- 2016
CX43蛋白在子宫内膜息肉中的表达及意义
|
Abstract:
摘要：目的 探讨CX43蛋白在子宫内膜息肉(EP)中的表达及意义。方法 随机选取存档石蜡标本共79例，为2011年1月至2013年5月于西安交通大学第二附属医院妇产科就诊的EP及因其他子宫内膜疾病诊刮患者的术后病检组织，其中病例组共44例EP组织(其中增殖期18例，分泌期15例，绝经后11例)，对照组共35例正常子宫内膜组织(其中增殖期12例，分泌期12例，绝经后11例)。采用免疫组化法检测CX43蛋白在正常子宫内膜及EP绝经前、后期的表达情况，并分析与临床指标的关系。结果 对照组及EP组中CX43蛋白的表达可见于子宫内膜腺上皮细胞及腺体周围的间质细胞中。EP组CX43蛋白阳性率较对照组降低，差异有统计学意义(P<0.05)。CX43蛋白在增殖期和分泌期EP中的阳性率相近，在绝经后EP中的阳性率较绝经前降低，但差异均无统计学意义(P>0.05)。EP中CX43蛋白的阳性表达与高血压及息肉数目无相关性。结论 CX43蛋白在EP中的表达降低，在EP发生发展过程中可能起着重要作用。
ABSTRACT: Objective To explore the expression of CX43 protein in endometrial polyps (EP). Methods We randomly selected 79 paraffin specimens of EP diagnosed at the Department of Obstetrics and Gynecology of the Second Affiliated Hospital, Xi’an Jiaotong University, from January 2011 to May 2013 after dilation and curettage of endometrial tissues by histopathological examination. They included 44 cases of EP tissues (18 cases in proliferational phase, 15 cases in secretory phase, and 11 cases in postmenopausal phase) and 35 cases of normal endometrial tissues as the control group (12 cases in proliferational phase, 12 cases in secretory phase, and 11 cases in postmenopausal phase). CX43 protein expression was analyzed in premenopausal and postmenopausal EP by immunohistochemical staining. Results The positive expression of CX43 protein in both control group and EP tissues was found in endometrial glandular epithelial cells and stroma cells surrounding the glands, principally in glandular epithelial cells. The positive rate of CX43 protein in the EP significantly decreased compared with control group in corresponding phase (P<0.05). The positive rate of CX43 protein in the proliferational and secretory stages was similar, but it decreased in postmenopausal stage compared to premenopausal phase of EP, but without significant difference (P>0.05). The positive expression of CX43 protein in EP had no correlation with hypertension and the number of polyps. Conclusion CX43 protein expression in endometrial polyps is reduced, which may play an important role in the development of EP
| [1] | PRESS MF, SAUTER G, BUYSE M, et al. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy[J]. J Clin Oncol, 2011, 29(7):859-867. |
| [2] | ZHOU W, LIU G, PARK S, et al. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer[J]. Cancer Epidemiol Biomarkers Prev, 2005, 14(2):491-496. |
| [3] | ETTINGER DS, AKERLEY W, BORGHAEI H, et al. Non-small cell lung cancer, version 2.2013[J]. J Natl Compr Canc Netw, 2013, 11(6):645-653. |
| [4] | O’GRADY S, FINN SP, CUFFE S, et al. The role of DNA repair pathways in cisplatin resistant lung cancer[J]. Cancer Treat Rev, 2014, 40(10):1161-1170. |
| [5] | BRASE JC, SCHMIDT M, FISCHBACH T, et al. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction[J]. Clin Cancer Res, 2010, 16(8):2391-2401. |
| [6] | CANALES RD, LUO Y, WILLEY JC, et al. Evaluation of DNA microarray results with quantitative gene expression platforms[J]. Nat Biotechnol, 2006, 24(9):1115-1122. |
| [7] | KNUDSEN BS, ALLEN AN, MCLERRAN DF, et al. Evaluation of the branched-chain DNA assay for measurement of RNA in formalin-fixed tissues[J]. J Mol Diagn, 2008, 10(2):169-176. |
| [8] | DAVIDOFF AM. Wilms’ tumor[J]. Curr Opin Pediatr, 2009, 21(3):357-364. |
| [9] | PASTORE G, ZNAOR A, SPREAFICO F, et al. Malignant renal tumours incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project[J]. Eur J Cancer, 2006, 42(13):2103-2114. |
| [10] | SAEBO M, SKJELBRED CF, NEXO BA，et al. Increased mRNA expression levels of ERCC1, OGG1 and RAI in colorectal adenomas and carcinomas[J]. BMC Cancer, 2006, 16(6):208-215. |
| [11] | OLAUSSEN KA, DUNANT A, FOURET P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J]. N Engl J Med, 2006, 355(10):983-991. |
| [12] | VILMAR A, GARCIA-FONCILLAS J, HUARRIZ M, et al. RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC[J]. Lung Cancer, 2012, 75(3):306-312. |
| [13] | TSODIKOV OV, JVANOV D,ORELLI B, et al. Structural basis for the recruitment of ERCCl-XPF to nucleotide excision repair complexes by XPA[J]. EMBO, 2007, 26(22):4768-4776. |
| [14] | FAUTREL A, ANDRIEUX L, MUSSO O, et al. Overexpression of the two nucleotide excision repair genes ERCC1 and XPC in human hepatocellular carcinoma[J]. J Hepatol, 2005, 43(2):288-293. |
| [15] | KOH Y, JANG B, HAN SW, et al. Expression of class Ⅲ beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer[J]. J Thorac Oncol, 2010, 5(3):320-325. |
| [16] | ZHANG HL, RUAN L, ZHENG LM, et al. Association between class Ⅲ β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis[J]. Lung Cancer, 2012, 77(1):9-15. |
| [17] | NAKAMURA L, RITCHEY M. Current management of Wilms’ tumor[J]. Curr Urol Rep, 2010, 11(1):58-65. |
